Asio Capital LLC Invests $3.28 Million in Becton, Dickinson and Company $BDX

Asio Capital LLC bought a new position in Becton, Dickinson and Company (NYSE:BDX) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 16,874 shares of the medical instruments supplier’s stock, valued at approximately $3,275,000.

Several other institutional investors and hedge funds have also modified their holdings of the business. Vanguard Group Inc. boosted its holdings in shares of Becton, Dickinson and Company by 0.5% in the 3rd quarter. Vanguard Group Inc. now owns 32,455,790 shares of the medical instruments supplier’s stock worth $6,074,750,000 after acquiring an additional 147,041 shares in the last quarter. State Street Corp raised its holdings in shares of Becton, Dickinson and Company by 3.4% in the third quarter. State Street Corp now owns 13,872,395 shares of the medical instruments supplier’s stock valued at $2,596,496,000 after buying an additional 459,219 shares during the last quarter. First Eagle Investment Management LLC raised its holdings in shares of Becton, Dickinson and Company by 13.8% in the third quarter. First Eagle Investment Management LLC now owns 9,994,408 shares of the medical instruments supplier’s stock valued at $1,870,653,000 after buying an additional 1,208,218 shares during the last quarter. Massachusetts Financial Services Co. MA raised its holdings in shares of Becton, Dickinson and Company by 7.5% in the third quarter. Massachusetts Financial Services Co. MA now owns 9,150,584 shares of the medical instruments supplier’s stock valued at $1,712,715,000 after buying an additional 636,138 shares during the last quarter. Finally, Wellington Management Group LLP raised its holdings in shares of Becton, Dickinson and Company by 9,056.3% in the third quarter. Wellington Management Group LLP now owns 5,232,086 shares of the medical instruments supplier’s stock valued at $979,290,000 after buying an additional 5,174,944 shares during the last quarter. 86.97% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research analysts recently issued reports on BDX shares. JPMorgan Chase & Co. cut their price target on Becton, Dickinson and Company from $190.00 to $175.00 and set a “neutral” rating for the company in a report on Tuesday, February 10th. Royal Bank Of Canada set a $172.00 price target on shares of Becton, Dickinson and Company in a report on Tuesday, February 10th. Bank of America raised their price target on shares of Becton, Dickinson and Company from $190.00 to $207.00 and gave the company a “neutral” rating in a report on Monday, January 5th. TD Cowen raised their price target on shares of Becton, Dickinson and Company from $183.00 to $189.00 and gave the company a “hold” rating in a report on Wednesday, February 11th. Finally, Barclays started coverage on shares of Becton, Dickinson and Company in a report on Tuesday, February 10th. They issued an “overweight” rating and a $202.00 price target for the company. Six investment analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Becton, Dickinson and Company has a consensus rating of “Hold” and an average price target of $191.62.

Becton, Dickinson and Company Price Performance

Becton, Dickinson and Company stock opened at $154.87 on Wednesday. The business’s 50-day simple moving average is $173.75 and its 200 day simple moving average is $186.01. The stock has a market cap of $44.10 billion, a price-to-earnings ratio of 25.26, a P/E/G ratio of 11.20 and a beta of 0.29. Becton, Dickinson and Company has a 12-month low of $127.59 and a 12-month high of $187.35. The company has a quick ratio of 0.58, a current ratio of 1.05 and a debt-to-equity ratio of 0.67.

Becton, Dickinson and Company (NYSE:BDX) last posted its quarterly earnings results on Monday, February 9th. The medical instruments supplier reported $2.91 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.81 by $0.10. Becton, Dickinson and Company had a return on equity of 15.76% and a net margin of 8.01%.The business had revenue of $4.49 billion for the quarter, compared to analysts’ expectations of $5.15 billion. During the same quarter last year, the business earned $3.43 earnings per share. The firm’s quarterly revenue was up 1.6% compared to the same quarter last year. Becton, Dickinson and Company has set its FY 2026 guidance at 12.350-12.650 EPS. As a group, research analysts anticipate that Becton, Dickinson and Company will post 14.43 earnings per share for the current year.

Becton, Dickinson and Company Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, March 31st. Investors of record on Tuesday, March 10th were issued a $1.05 dividend. This represents a $4.20 annualized dividend and a yield of 2.7%. The ex-dividend date was Tuesday, March 10th. Becton, Dickinson and Company’s dividend payout ratio is currently 68.52%.

Becton, Dickinson and Company announced that its board has approved a share repurchase plan on Tuesday, January 27th that authorizes the company to repurchase $10.00 million in shares. This repurchase authorization authorizes the medical instruments supplier to buy up to 0% of its stock through open market purchases. Stock repurchase plans are typically a sign that the company’s management believes its stock is undervalued.

Insider Activity at Becton, Dickinson and Company

In related news, Director Bertram L. Scott sold 953 shares of the company’s stock in a transaction dated Wednesday, February 18th. The stock was sold at an average price of $182.61, for a total value of $174,027.33. Following the completion of the sale, the director owned 36,763 shares in the company, valued at approximately $6,713,291.43. This represents a 2.53% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, EVP Michael David Garrison sold 1,610 shares of the company’s stock in a transaction dated Thursday, January 15th. The shares were sold at an average price of $207.46, for a total value of $334,010.60. Following the completion of the sale, the executive vice president owned 12,095 shares of the company’s stock, valued at $2,509,228.70. This represents a 11.75% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 2,713 shares of company stock worth $536,881 over the last 90 days. 0.40% of the stock is currently owned by company insiders.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.